

Group IV in a Restriction Requirement dated February 11, 1997 in connection with the parent application. The new claims are supported by the specification at page 36, line 28 to page 39, line 2. More specifically, the polypeptide recited in Claim 34 is described in Figure 3A-3E. The polypeptide recited in Claim 42 is described in Figure 12A-12E. The polypeptide recited in Claim 50 is described in Figure 4A-4C. The polypeptide recited in Claim 58 is described at page 49, lines 23-27 and in Figure 11. Claims 36-38, 44-46, 52-54 and 60-62 are described at page 36, lines 30-33, and page 38, lines 1-11 and lines 28-37. Claims 39, 47, 55 and 63 are described at page 25, lines 32-34. Claims 40, 48, 56 and 64 are described at page 25, line 36 to page 26, line 2. No new matter has been introduced by the new claims.

The title of the application has been amended to reflect the presently claimed invention. The specification has been amended to insert up-dated priority information. The amendments do not introduce new matter.

Applicants respectfully request that this Amendment be made of record in the file history of the instant application.

Respectfully submitted,

Dated: January 25, 1999

Brian M. Poissant by V. V. V. V.  
Brian M. Poissant Reg. No. 35,750  
28,462  
(Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosure